A small glass vial with a gold cap labeled Tirzepatide 10 mg in black text, containing a white powder, on a plain background.

BATCH

PURITY

99% HPLC

GLP-2 (T)

Name: GLP-2 (T) - Simon's Compounding
Availability: InStock

Cardiovascular HealthGlycemic ControlNeuroprotectionWeight Management

Price range: $250.00 through $850.00

Weight/Mass

Clear

Volume Pricing Guide

Title	QUANTITY	PRICE PER
Bulk/tiered discount	1	0% $250.00
Bulk/tiered discount	2 - 4	10% $225.00
Bulk/tiered discount	5 - 9	15% $212.50
Bulk/tiered discount	10 - 14	20% $200.00
Bulk/tiered discount	15 - 19	25% $187.50
Bulk/tiered discount	20 +	30% $175.00

Only the lyophilized product is provided. For research use only. All supplies sold separately.

Summary

Tirzepatide is a groundbreaking dual-incretin mimetic that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, amplifying the body’s natural metabolic regulation. Tirzepatide has redefined treatment paradigms for diabetes and obesity. Clinical trials demonstrate unprecedented weight loss of up to 22.5% of body weight over 72 weeks, rivaling the outcomes of bariatric surgery, alongside a 2.0–2.4% reduction in HbA1c, achieving glycemic control unparalleled in current diabetes treatments (1, 2, 3). By mirroring and enhancing natural physiological processes, Tirzepatide enables a transformative shift toward metabolic balance, inspiring confidence in its potential to elevate both health and quality of life (4, 5).

Research Recommendations

Batch Testing Reports

Tirzepatide

Description & Pharmacodynamics

GLP-2 (T)’s dual mechanism of action enables synergistic activation of GIP and GLP-1 pathways, targeting critical metabolic functions:

GIP Receptor Activation (1, 3):
- Enhances insulin sensitivity and secretion.
- Improves lipid metabolism, reducing postprandial triglycerides and cholesterol levels.
GLP-1 Receptor Activation (2, 4):
- Promotes glucose-dependent insulin secretion.
- Suppresses glucagon secretion, reducing hepatic glucose output.
- Reduces appetite via central nervous system pathways and slows gastric emptying.

This combination leads to sustained glycemic control, substantial weight loss, and systemic benefits, including cardiovascular and neuroprotective effects (3, 5).

Pharmacokinetics
GLP-2 (T) features structural modifications that extend its half-life (~5 days), enabling once-weekly dosing for optimal bioavailability and patient adherence (1).

Research Insights

1. Glycemic Control

GLP-2 (T) achieved HbA1c reductions of 2.0–2.4% in the SURPASS trials, with 91% of patients reaching HbA1c levels <7% (1, 2).
It preserves pancreatic beta-cell function, offering long-term benefits in Type 2 diabetes management (3).

2. Weight Management

Participants in the SURMOUNT trials experienced up to 22.5% total body weight reduction over 72 weeks, far exceeding results from existing GLP-1 therapies (2).
The combination of appetite suppression, delayed gastric emptying, and enhanced metabolic efficiency drives these outcomes (4).

3. Cardiovascular Benefits

Early studies reveal reductions in systolic blood pressure, LDL cholesterol, and C-reactive protein, markers critical to cardiovascular health (4, 5).
GLP-2 (T) has shown potential to improve left ventricular function and reduce long-term cardiovascular risks (5).

4. Neuroprotection

Preclinical research suggests GLP-2 (T) mitigates amyloid-beta plaque formation, slows cognitive decline, and promotes neuronal survival, offering potential benefits in Alzheimer’s disease (6).

5. Non-Alcoholic Fatty Liver Disease (NAFLD)

GLP-2 (T) demonstrated a significant reduction in hepatic fat content and liver inflammation, underscoring its potential in treating NAFLD and NASH (5).

Structure

Sequence: Synthetic 39-amino acid polypeptide optimized for dual receptor activity.
Molecular Formula: C225H348N48O68
Molecular Weight: ~4813.5 g/mol
PubChem CID: 147200515

Citations for GLP-2 (T)

Glycemic Control

Frias, J. P., et al. Efficacy and Safety of GLP-2 (T) in Type 2 Diabetes. Lancet Diabetes & Endocrinology, 2021.
Jastreboff, A. M., et al. GLP-2 (T) for Glycemic Control and Weight Loss. New Engl J Med, 2022.

Weight Management

Nauck, M. A., et al. Dual Incretin Receptor Agonists and Obesity Therapy. Diabetes Care, 2022.

Cardiovascular Benefits

Rosenstock, J., et al. Effects of GLP-2 (T) on Cardiovascular Risk Markers. JAMA, 2022.

Neuroprotection

Drucker, D. J. Incretin Hormones and Cognitive Preservation. Nature Reviews Endocrinology, 2020.

NAFLD and Liver Health

Newsome, P. N., et al. Emerging Therapies for NAFLD and NASH: Focus on GLP-2 (T). Hepatology, 2021.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.